Pharma Sector : Attractive Medium to Long Term Opportunity!
An assessment of medium-to-long-term opportunities across the Pharma sector, with a broader strategic view on IT, FMCG, Auto, and PSU sectors amid evolving valuation and growth dynamics.
Our Recent Calls & Overweights
A review of WealthSpring’s recent sector overweight calls amid the second COVID wave and their strong performance across banking, pharma, PSU, and gold.
Wealthspring Sectoral Overweight’s – Significant Outperformance
WealthSpring’s early and sustained overweight to Public Sector Enterprises (PSEs) has delivered strong absolute and risk-adjusted returns, validating its sectoral allocation framework.
Our Sector wise Take
A sector-wise investment perspective during COVID-19, highlighting selective opportunities in banking, IT, pharma, and PSUs amid heightened volatility and valuation dislocations.
Pharma & Healthcare Sector to Outperform
Pharma and healthcare are positioned to outperform, supported by rising healthcare infrastructure spending, improving pharma valuations, and structural tailwinds across domestic formulations, APIs, and US generics.
Public sector enterprise (PSE/PSU companies) offer a compelling pocket of opportunity for investment
Public sector enterprises (PSEs) are trading at deep valuation discounts despite strong balance sheets, healthy dividend yields, and potential re-rating triggers from strategic divestments.
Pharma Sector: Good Buying Opportunity!
After a prolonged downturn driven by US generics pressure and regulatory challenges, the Indian pharma sector appears to be at an inflection point with improving fundamentals, currency tailwinds, and stabilizing US operations.
Pharma Sector sell off is a buying opportunity last week
Recent earnings disappointments and regulatory concerns have led to a sharp sell-off in Indian pharma stocks, creating an attractive opportunity to build sector exposure amid stabilising US generics dynamics and long-term growth drivers.